Wegovy Pharmacokinetics (ADME): How Semaglutide 2.4 mg Is Absorbed, Distributed, Metabolized, and Excreted

Wegovy delivers semaglutide 2.4 mg as a once-weekly subcutaneous injection belonging to the GLP-1 receptor agonist class. The FDA has approved Wegovy for chronic weight management in adults with BMI 30 kg/m² or greater, or BMI 27 kg/m² or greater plus at least one weight-related comorbidity, as well as adolescents aged 12 and older who meet defined weight thresholds. Wegovy contains the same active ingredient as the diabetes medications Ozempic and Rybelsus, though those drugs use different semaglutide doses and Rybelsus employs oral rather than injectable delivery. This article reviews how Wegovy is absorbed, distributed, metabolized, and excreted based on FDA-approved prescribing data, while distinguishing between findings supported by clinical evidence and theoretical mechanisms that lack bedside confirmation.

The core, quotable fact set: Wegovy (semaglutide 2.4 mg) is absorbed slowly from a subcutaneous depot, peaks in plasma at 1 to 3 days, reaches steady state after about a month of once-weekly dosing, and is eliminated with a half-life of approximately one week, according to the FDA-approved label for NDA 215256 (approved June 2021). Its long half-life comes from near-total albumin binding and resistance to the enzyme that rapidly destroys native GLP-1, and this is also why no CYP450 drug-interaction pathway exists for this drug. That combination is the reason dosing is weekly rather than daily, and it is the boundary within which every other pharmacokinetic claim on this page should be read.

The question this page actually answers

A generic ADME summary lists numbers. The more useful question for a prescriber or patient is: which of these pharmacokinetic facts should change a real decision, and which are background physiology with no bedside consequence? For example, the near-total albumin binding is interesting biochemistry, but the decision-relevant fact drawn from it is narrower: intact semaglutide is not renally filtered, which is why the label does not require a renal dose adjustment. Meanwhile, a claim like "a 100 kg patient clears the drug 20% faster than a 70 kg patient" may appear in secondary sources, but unless a reader can trace it to the current label or a verifiable population-PK publication, it should be treated as unconfirmed and not used to justify off-label dose changes.

Absorption: getting from the injection site into the bloodstream

Subcutaneous semaglutide is absorbed slowly from the injection depot. Peak plasma concentration is reached roughly 1 to 3 days after a dose, per the FDA-approved label for Wegovy. Absolute subcutaneous bioavailability is commonly cited in the pharmacology literature as approximately 89%, though this specific figure should be verified against the current label text rather than assumed from secondary summaries.

Injection site. Clinical dosing across the abdomen, thigh, and upper arm is treated as pharmacokinetically interchangeable in FDA-approved dosing instructions; site rotation is recommended for skin tolerability, not because one site is known to absorb the drug faster or slower. Injecting into visibly scarred or lipodystrophic tissue is a plausible reason for reduced local absorption, but this is inferred from general injection pharmacology, not a semaglutide-specific study cited here.

Dose escalation. The label's escalation schedule, starting near 0.25 mg and increasing over months to 2.4 mg, changes how much drug is delivered per injection, not how quickly it is absorbed. Exposure rises with dose across the approved range, which is the basis for why the schedule works as a gradual ramp rather than a single jump to the maintenance dose.

Distribution: where the drug goes once absorbed

Volume of distribution. Semaglutide's apparent volume of distribution is small, commonly reported near 12.5 liters, close to plasma volume itself. This indicates the drug stays largely in the vascular compartment rather than spreading widely into peripheral tissue, which is consistent with (though not identical to) similarly engineered long-acting GLP-1 analogues.

Albumin binding. More than 99% of circulating semaglutide is bound to plasma albumin. This is the central mechanistic fact behind the long half-life: bound drug is protected from rapid clearance and is released slowly. It is also why intact drug is not filtered by the kidney glomerulus, which underlies the renal dosing guidance discussed below.

Central nervous system effects. GLP-1 receptors are expressed in the hypothalamus and brainstem, and central receptor activity is considered a key contributor to semaglutide's appetite-suppressing effect. The generally accepted explanation is that semaglutide reaches these receptors through circumventricular organs (regions such as the area postrema and parts of the hypothalamus that sit outside the conventional blood-brain barrier) rather than through broad blood-brain barrier crossing. This is a widely cited mechanistic model in GLP-1 pharmacology, but the precise proportion of weight loss attributable to central versus peripheral (gastric) effects in humans is not settled by a single definitive human study and should be described as a plausible mechanism rather than a fixed percentage.

Mechanism of action: what happens at the receptor

Semaglutide activates the GLP-1 receptor, a G-protein-coupled receptor found in the pancreas, gut, brain, heart, and kidney. In the pancreas, this glucose-dependent stimulation of insulin release and suppression of glucagon is why semaglutide alone carries relatively low intrinsic hypoglycemia risk, though risk rises when combined with insulin or sulfonylureas.

Semaglutide also slows gastric emptying, an effect most pronounced early in treatment. Some pharmacodynamic studies of semaglutide and related molecules describe partial normalization of gastric emptying effects over months even while drug concentration remains steady, suggesting durable weight-loss efficacy depends substantially on appetite regulation rather than on persistent delayed stomach emptying alone. The exact magnitude and time course of this tachyphylaxis reported in specific trials should be confirmed against the primary publication before being quoted as a precise percentage.

Decision framework: when does a PK fact actually change what you should do?

Most readers of a pharmacokinetics page are not trying to memorize numbers; they are trying to decide something. The table below separates PK facts that have a direct, defensible action attached to them from facts that are interesting background with no independent decision consequence. Anything in the "verify before acting" column should not be used to justify a dosing change without checking the current label or a clinician.

Steady state and the weight-loss timeline

Steady-state plasma concentration is reached after roughly 4 to 5 weeks of once-weekly dosing at a given dose level. Because the approved escalation schedule steps up the dose every few weeks over several months, patients do not reach full steady-state exposure at the 2.4 mg maintenance dose until well into the escalation period, commonly cited as somewhere in the fourth to sixth month of treatment. This is consistent with the general shape of weight-loss curves reported in the pivotal phase 3 program, where most of the weight change accumulated well after the first month rather than immediately. Readers should treat exact week-by-week percentages attributed to specific trial arms as needing verification against the primary trial publication and the current FDA label rather than treating a single secondary summary as definitive.

Metabolism: no liver enzyme pathway

Semaglutide is not metabolized by cytochrome P450 enzymes. It is broken down instead through sequential proteolytic cleavage of the peptide backbone, with additional minor clearance through oxidation of its fatty acid side chain. This is the structural basis for the drug's low potential for classic drug-drug interactions: there is no CYP substrate, inhibitor, or inducer relationship to manage.

Structurally, semaglutide differs from native human GLP-1 (which has a plasma half-life measured in minutes) through an amino acid substitution that blocks the enzyme that normally destroys GLP-1 within minutes, plus a fatty acid chain that promotes albumin binding. Together these modifications are why the half-life extends from minutes to roughly a week. The exact quantitative reduction in enzymatic cleavage attributable to the amino acid substitution is reported in the pharmacology literature but is not repeated here as a specific percentage without a verified primary source.

Excretion: urine, feces, and why intact drug rarely appears in either

Semaglutide and its breakdown products are eliminated through both urine and feces, consistent with a peptide that is broken down into smaller fragments before excretion rather than filtered whole. Because more than 99% of circulating drug is albumin-bound, what appears in urine is understood to be small peptide metabolites rather than intact semaglutide, since bound drug does not pass the glomerular filter. Specific percentage splits between urine and fecal recovery reported from radiolabeled-drug studies exist in the literature but should be confirmed against the primary source before being cited as an exact figure.

Renal impairment. The FDA label for Wegovy states no dose adjustment is needed across studied levels of renal impairment, including patients on dialysis. This is one of the more clinically load-bearing facts on this page because it directly answers a common prescribing question.

Hepatic impairment. Similarly, no dose adjustment is required for hepatic impairment according to the label, based on studies across mild, moderate, and severe impairment categories.

Drug interactions: what actually changes with co-administration

Because semaglutide is not a CYP450 substrate, classic pharmacokinetic drug-drug interactions are uncommon. The interaction pathway that does exist is indirect, through delayed gastric emptying, which can slow the rate of absorption of some oral medications without necessarily reducing the total amount absorbed. Medications commonly flagged for monitoring on this basis include oral thyroid hormone and oral contraceptives; the current FDA label for the oral semaglutide product (Rybelsus) explicitly flags reduced ethinylestradiol exposure, and the same gastric-emptying mechanism is the basis for caution with subcutaneous Wegovy, though this should be confirmed against the current Wegovy label rather than assumed identical.

Co-prescription with insulin or sulfonylureas does not change semaglutide's own pharmacokinetics. The relevant interaction is pharmacodynamic: additive blood glucose lowering, which raises hypoglycemia risk and is a reason to discuss dose adjustment of the other agent with a prescriber, not semaglutide itself.

Special populations

Body weight. Some population pharmacokinetic analyses associate higher body weight with modestly higher semaglutide clearance. Whether this meaningfully changes outcomes at the fixed 2.4 mg dose is not established from the data summarized here, and any specific percentage difference in clearance by weight category should be verified against a primary population-PK publication before being treated as clinically actionable.

Older adults. Age has not been shown to meaningfully affect semaglutide exposure in the populations studied to support approval, and the label does not require age-based dose adjustment.

Adolescents. Wegovy is FDA-approved for adolescents 12 years and older as of December 2022, based on a dedicated adolescent trial. The label states the exposure-response relationship in this age group is consistent with adults and does not require a different dose.

Pregnancy and lactation. Animal studies showed fetal harm at exposures above the human therapeutic range, and Wegovy is not recommended during pregnancy. Whether semaglutide passes into human breast milk has not been established through controlled studies; the label reflects this uncertainty rather than an established answer, and lactating patients should discuss this directly with their prescriber.

Missed doses: the pharmacokinetic logic behind the 5-day rule

The label instructs that if fewer than 5 days remain before the next scheduled dose, the missed dose should be skipped rather than taken late. This is broadly consistent with a roughly week-long half-life: taking a dose very close to the next scheduled one would layer two doses' worth of drug close together, risking transiently higher concentrations and worse gastrointestinal side effects without a clear efficacy benefit. This is a reasonable mechanistic explanation for the rule, not a claim that HealthRX.com has independently modeled; the operative instruction for patients is the label's day-count rule itself, not a self-calculated exposure estimate.

How semaglutide's PK compares across the GLP-1 class

Figures are commonly cited approximations from each product's own FDA-approved labeling and should be checked against the current label for the specific drug before being used for a clinical comparison, since labels are updated periodically. Wegovy's regulatory record is available through the FDA's application overview.

What is established, what is plausible, and what is not established

Established, from the FDA-approved label: approximate Tmax of 1 to 3 days, approximate half-life near one week, steady state after roughly 4 to 5 weekly doses, greater than 99% albumin binding, no CYP450 metabolism, no required dose adjustment for renal or hepatic impairment across studied categories, and the 5-day missed-dose rule.

Plausible but not fully quantified from a single confirmed source in this draft: the precise percentage split between urinary and fecal excretion, the exact percentage reduction in enzymatic cleavage from the drug's structural modifications, the exact percentage of weight-loss effect attributable to central versus gastric mechanisms, and the exact percentage change in clearance associated with body weight. These mechanisms are reasonable and consistent with the broader GLP-1 pharmacology literature, but specific numbers attached to them should be verified against a named primary source before being repeated as settled facts.

Not established: whether semaglutide transfers into human breast milk in clinically meaningful amounts, and the precise individual timeline of weight loss for any specific patient, since trial averages do not predict an individual's response.

Clinical takeaways

1. The 7-day-range half-life is why dosing is weekly and why a missed dose more than 5 days out should simply be taken, not doubled up.
2. Near-total albumin binding is the reason no renal dose adjustment is needed, not a coincidence.
3. No CYP450 metabolism means most drug interactions are pharmacodynamic (additive glucose lowering) or indirect (slowed gastric emptying), not classic enzyme-based interactions.
4. Full maintenance-dose steady state is not reached until the escalation schedule is complete, which is a reasonable basis for setting patient expectations about timeline, not for predicting individual results.
5. Several mechanistic claims in circulation about exact percentages (excretion split, clearance-by-weight, central-versus-peripheral effect) need primary-source verification before being treated as fixed numbers in patient counseling.

References

• FDA approval and application record for Wegovy (semaglutide), NDA 215256: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

Several numeric claims in earlier drafts of this page (exact excretion percentages, exact clearance-by-weight figures, exact percentage of central versus peripheral effect, and specific trial-arm percentages) could not be traced to a verifiable primary source in this revision and have been narrowed or flagged rather than repeated as precise figures. These should be checked against the current FDA label and named primary publications during medical review before restoring any specific number.